RxDoctor Payments Data

Ricardo Blondet Vissepo, MD

Internal Medicine · Ponce, PRNPI 1679594337

Payments from drug & device makers

$4,830in general payments, 2019–2025

Across 83 payments — averaging $58.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Sanofi-aventis U.S. LLC$317
  • AstraZeneca$257
  • PBG Puerto Rico LLC$214
  • GSK$194
  • plus $452 from 8 others

What the payments were for

  • Consulting fees$2,70056%
  • Speaking & faculty fees$2004%
  • Travel & lodging$2014%
  • Food & beverage$1,72436%
  • Education$50%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson12$2,108
E.r. Squibb & Sons, L.L.C.10$1,288
Sanofi-aventis U.S. LLC8$317
AstraZeneca11$257
PBG Puerto Rico LLC11$214
GSK4$194
Boehringer Ingelheim11$167
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)9$129
Sanofi1$43
AbbVie2$33
Dexcom, Inc.1$26
Novo Nordisk1$24
Pfizer Pharmaceuticals LLC1$15
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,830 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$1,216
Medicare patients
11
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol13$15,120
LantusInsulin Glargine,hum.Rec.Anlog21$3,470
SynthroidLevothyroxine Sodium53$3,267
Atorvastatin Calcium106$1,627
Famotidine167$1,445
Gabapentin175$1,342
Omega-3 Acid Ethyl Esters25$1,248
Albuterol Sulfate HfaAlbuterol Sulfate23$1,016
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$951
Metoprolol Succinate37$756
Levothyroxine Sodium48$725
Losartan Potassium46$679
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide24$656
Tamsulosin Hcl60$584
Clonazepam52$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$257$15,12013 claims
Sanofi-aventis U.S. LLCLantus$317$3,47021 claims
AbbVieSynthroid$33$3,26753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →